<DOC>
	<DOCNO>NCT00952393</DOCNO>
	<brief_summary>The study determine new preparation drug design treat schizophrenia slowly release body .</brief_summary>
	<brief_title>Nicotinic Receptors Schizophrenia</brief_title>
	<detailed_description>3-2,4 dimethoxybenzylidene compound methyallose compound dose 150 300 mg . The capsule administer singly eventually bid determine sustain blood level comparable steady state blood level see previous study determine . Safety EEG effect measure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy volunteer : male female incapable pregnancy Medical illnesses require acute treatment History seizures Substance abuse include nicotine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>receptor nicotinic</keyword>
</DOC>